NGS Testing from
Solid Biopsy

Precision Cancer Genomic
Profiling with Tissue Biopsy

NGS Testing from Solid Biopsy

Comprehensive Cancer
Genomic Profiling with Solid
and Liquid Biopsies

NGS Testing from Solid Biopsy

Precision Cancer Genomic
Profiling with Tissue Biopsy

Why NGS Testing from Solid Biopsy
is Essential in Cancer Genomic Profiling

Solid biopsy, or tissue biopsy, remains a cornerstone in comprehensive genomic profiling by offering direct insights into the molecular architecture of a tumor. Analyzing DNA extracted from tumour tissue or Formalin-Fixed, Paraffin-Embedded (FFPE) blocks preserved following biopsy, it provides localized, tumor-specific data, making it indispensable for primary diagnosis and guiding initial treatment strategies in precision oncology.

Solid Biopsy Tests Portfolio

TARGT First

TARGT First is one of the most focused pan-solid cancer NGS Testing from Solid Biopsy, encompassing 72 of the most commonly mutated cancer-associated genes with a high level of evidence for both targeted therapy and prognostication.
TARGT First offers end to end sequencing covering complete gene sequence for most of the genomic biomarkers for which NCCN and FDA-approved therapy options are available for the treatment of solid cancers.

TARGT Indiegene

TARGT Indiegene is one of the largest cancer gene panels almost 1/10th the size of whole exome (~4.2Mb panel size) covering well-known oncogenic driver mutations and other oncogenic variations having clinical and research value.
TARGT Indiegene analyzes 1212 unique genes, including genes for SNVs/Indels, CNAs, Gene-Fusions, which include common and rare fusions as well as novel fusion partners along with Immunotherapy Biomarkers (TMB, MSI by NGS, and PD-L1 by IHC).

TARGT Absolute

TARGT Absolute is a cutting-edge CGP test that analyzes ~20,000 genes from tissue (DNA/RNA) and germline DNA, offering an extensive understanding of tumor biology. By leveraging whole-exome sequencing, the test identifies critical genetic variations, including coding mutations and regulatory elements, providing comprehensive insights into cancer mechanisms and heterogeneity.
TARGT Absolute incorporates advanced features such as AI/ML-driven Therapy Response Index (TRI), TMB/MSI evaluation, and regulatory element analysis. Using Cellworks’ proprietary AI/ML algorithm, the test generates TRI and pathway analysis through the Cellworks Ventura™ report, delivering actionable insights. This ensures a personalized cancer care approach aligned with each patient’s unique molecular cancer profile.

Advantages of NGS Testing from Solid Biopsy in Cancer Treatment

Accurate Tumor-Specific Genomic Profiling

NGS Testing from Solid Biopsy provides direct access to the tumor tissue, allowing for precise analysis of genetic mutations and biomarkers specific to the primary tumor. This accuracy supports targeted treatment planning based on the tumor’s unique genomic profile.

Comprehensive Data on Primary Tumor Site

By analyzing multiple regions within the tumor, solid biopsies capture the genetic diversity within cancer cells, which is crucial for understanding tumor heterogeneity and resistance mechanisms that may affect treatment responses.

Guidance for Initial Diagnosis and Treatment Strategy

NGS Testing from Solid Biopsy offers detailed insights essential for initial cancer diagnosis and staging. This data enables oncologists to develop a more effective, individualized treatment plan right from the start, improving patient outcomes.

High Relevance for FDA-Approved Biomarkers

NGS Testing from Solid Biopsy are particularly effective for identifying biomarkers that align with FDA-approved therapies, ensuring compatibility with established treatment options and facilitating access to targeted therapies tailored to the patient’s cancer type.

Get Started with NGS Testing from Solid Biopsy

Contact us today to learn more about which NGS Tests from Solid Biopsy are right for you.

Consult Now
loader